Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study

Fig. 1

Study design. aIn addition to the assessments also performed at baseline, the screening period includes: obtaining/evaluating informed consent/assent; inclusion/exclusion criteria; genotyping; demographic information; medical history; and assessment of medications/therapies. bHeight and weight were measured at baseline and at months 12 and 24 only. AE, adverse event; BSID-III, Bayley Scales of Infant Development, Third Edition; DAS-II, Differential Ability Scales, Second Edition; HRQoL, health-related quality of life; HS-FOCUS, Hunter Syndrome Functional Outcomes for Clinical Understanding Scale; VABS-II, Vineland Adaptive Behavior Scales, Second Edition

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172